AYX-101

AYX-101 is an investigational preclinical **TCNP encapsulated red cell therapy** being developed by **Ayma Therapeutics** for **idiopathic pulmonary fibrosis**. The program uses Ayma's transcellular nanoparticle platform, in which a therapeutic payload is encapsulated within red blood cells to enable sustained and potentially targeted delivery; however, the specific payload and molecular target for AYX-101 have not been publicly disclosed. Based on the company pipeline description, AYX-101 is best characterized as a red cell-encapsulated nanoparticle therapeutic for pulmonary fibrosis rather than a conventional small molecule or antibody drug.

Other names

TCNP encapsulated red cell therapyred cell-encapsulated nanoparticle